> Protalix BioTherapeutics talked up the prospect of filing for approval of PRX-102 in Fabry disease. The Israeli biotech is continuing to enroll patients in studies of the modified version of recombinant alpha-Galactosidase-A protein but thinks it already has enough subjects for a quickie approval. Release
> Orchard Therapeutics’ IPO haul hit $225 million (€200 million) following the partial exercise of the underwriters’ option. Statement
> Novo Nordisk entered into a research collaboration with Embark Biotech. The Danish compatriots will work to discover treatments for obesity and metabolic disease. Release
> Acacia Pharma re-filed for approval of Barhemsys. Statement
> Onxeo posted phase 1 data on its DNA damage response inhibitor. The data tee Onxeo up to expand its clinical program next year. Release
> Acesion Pharma committed to initiating a phase 2 trial of cardioversion therapy AP30663 next year. The Danish biotech outlined the plans after posting phase 1 data on the atrial fibrillation drug. Statement